GRAIL, Inc. (GRAL): A Bull Case Theory

We came across a bullish thesis on GRAIL, Inc. on Valueinvestorsclub.com by skimmer610. In this article, we will summarize the bulls’ thesis on GRAL. GRAIL, Inc.'s share was trading at $32.42 as of September 3^rd.

GRAIL (NASDAQ: GRAL) represents a compelling risk-reward opportunity in early cancer detection through its Galleri blood test, the first commercially viable multi-cancer early detection (MCED) platform. The company, spun out of Illumina in 2016 and recently spun off again in 2024, has $678 million in cash and a $320 million annual burn rate, with a market cap of $1.6 billion and enterprise value of $900 million.

Galleri addresses a massive market, with over 100 million Americans eligible for screening and a global TAM exceeding $150 billion. Priced at $949 per test, the platform demonstrates strong gross margin potential even if prices fall to $500, and near-term revenues are growing rapidly, up 39% YoY in Q4 2024, supported by partnerships with Quest, Tricare, and life insurers.

Galleri leverages cfDNA methylation sequencing and machine learning to detect 50+ cancers, supported by Illumina’s bioinformatics IP and a proprietary 300K-sample biospecimen dataset, creating a defensible data moat. Clinical traction is strong, with 137K tests sold in 2024 and ongoing PATHFINDER-2 and NHS-Galleri trials.

Statistical analysis of combined trial data predicts ~350 early cancers detected from 175K patients, significantly shifting late-stage incidence and supporting FDA approval. Published studies show high specificity (99.5%) and strong sensitivity across multiple cancers, far exceeding competitors.

Key catalysts over the next 12–18 months include final PATHFINDER-2 results, FDA PMA filing, CMS reimbursement clarity, and NHS coverage decisions. Valuation scenarios range from $28/share in a bear case to $310/share in a bull case, with a base case of $145/share reflecting steady payer adoption. While regulatory and reimbursement risks exist, GRAL’s validated technology, first-mover advantage, massive market, and strong trial data suggest asymmetric upside, positioning the stock for significant gains as it approaches its pivotal 2025–2026 inflection window.

Previously we covered a bullish thesis on GRAIL, Inc. (GRAL) by mike-some in April 2025, which highlighted the company’s leadership in multi-cancer early detection, the spin-off from Illumina, promising PATHFINDER trial results, and potential Medicare/NHS reimbursement driving significant sales. The stock has appreciated ~25% since coverage. Skimmer610 shares a similar bullish view but emphasizes detailed financials, trial statistics, and near-term FDA and CMS catalysts.

GRAIL, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 25 hedge fund portfolios held GRAL at the end of the first quarter which was 28 in the previous quarter. While we acknowledge the potential of GRAL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.

Disclosure: None.